NEW YORK, April 15, 2021 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced that it will participate in the B. Riley Securities'
Neuroscience Conference, April 28-29,
2021.
Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET.
The B. Riley Securities' Neuroscience Conference will cover key
topics across neurodegeneration, neuropsychiatry, and mental health
disease areas, with both public and private healthcare companies.
For more information about the conference:
https://brileyfin.com/events
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral
sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other
psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference-301269110.html
SOURCE Seelos Therapeutics, Inc.